1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
M. De Miguel, Noboru Yamamoto, Judith Raimbourg, B.C. Cho, M. Gottfried, S.M. Stemmer, J.W. Goldman, Martha Blaney, Theodore S. Jennaro, Athanasios Vasilopoulos, R.R. Li, Kevin J. Freise, Martha Raluca Neagu Aristide, G. Morrison-Thiele, Z.N. Hunter, Michael C. Burns, D. Ross Camidge
Topics & Concepts
MedicineAntibody-drug conjugatenon-small cell lung cancer (NSCLC)ConjugateOncologyCancer researchLung cancerWild typeInternal medicineAntibodyImmunologyMonoclonal antibodyGeneMathematical analysisChemistryMutantBiochemistryA549 cellMathematicsLung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchRadiomics and Machine Learning in Medical Imaging